#ASH23 a point I had totally missed - thanks Mateo Mejia! For those implementing GRIFFIN or PERSEUS for #MMsm, we suggest GRIFFINDOR (named by Gurbakhash Kaur): 👉🏼 Dara per label 👉🏼 V D1,8,15 (I sometimes drop D8 dose once in VGPR) 👉🏼 R 21/28 days 👉🏼 dex 20mg once-weekly to off

Me during a conference: "I am so motivated, I will work on the plane back home and respond to all emails" Me on the plane:

#ASH23 in a nutshell🤣

NEW: a cohort study on CCUS suggests high-risk mutations and their number are predictive of survival warranting clinical surveillance & advises mutation analysis in patients with available bone marrow samples #cytopenias thelancet.com/journals/lanha…

Outcomes with Allogeneic Hematopoietic Stem Cell Transplantation in TP53-mutated MDS sciencedirect.com/science/articl…

🔥 Our clinical trial of metronomic low-dose decitabine-ven in frontline MDS/ AML shows low tox, high efficacy & high response rate in TP53 mutant pts!! pubmed.ncbi.nlm.nih.gov/39316768/ Amit Verma Aditi Shastri, MD Ioannis Mantzaris Marina Konopleva Yogen Saunthararajah Montefiore Health System Albert Einstein College of Medicine - Official #leusm

Next up, Jordan Snyder presenting #ASH24 poster 2411 on teclistamab in BCMA therapy exposed vs naive in RRMM! KU Cancer Center James Davis, PharmD, BCOP Al-Ola A Abdallah MD (USMIRC) Nausheen Ahmed MD Muhammad Umair Mushtaq (Abu Mikael) #oncopharm

So proud of Daniel Peters UNC Lineberger for a stellar presentation at #ASH24 on outcomes of CPX in younger AML pts w/ MDS mutations. Younger pts w/ AML & MDS mu had better outcomes w/ CPX despite equivalent alloBMT rates. AK Eisfeld Yazan Madanat, MD Michael Hochman

First thing I did getting to #ASH24 in San Diego? Getting Tacos 🌮 🌮 in Tacos el gordo, the best!

Great presentation Ioannis Mantzaris Montefiore Einstein Department of Medicine presenting on 7+3 and Venetoclax in #AMLsm with CR rates of 80% with 85% MRD negativity #ASH24

AML genomic data pooling between 🇺🇸MARROW consortium 🤝 🇲🇽GTLA led by Jesús G Lugo to clarify the meaning of “hispanic” #ASH24. Mexicans working together in both sides of the Rio Bravo (Grande) Nidia Zapata #Leusm

Best thing to do during SD #ASH24 eat tacos 🌮 🌮, and best in Tijuana!

Great and varied session about menin inhibitors, bleximenib 33% CRc in R/R MLL and NPM1mut #AMLsm Enzomenib CRc 48% MLL, 47% NPM1, no dose reduction for azoles, 7+3/Zifto 100% CRc! In NPM1 #ASH24 Joshua Zeidner MD Emma Searle Amer Zeidan MBBS,MHS ‏عامر زيدان

The success of blinatumomab in first line ALL continues. The next step is working for global access and equity! Humans with leukemia should not die just because of where they were born. Read ASH NEWS out now: tinyurl.com/yz8cpxh6 #ASH24

#myeloMATCH MM1YA-S01 is enrolling adults ages 18-59 with newly diagnosed high-risk #AML. Randomized 5-arm comparison of induction therapies. Primary endpoint: MRD-negative complete remission rate. SWOG.org/clinical-trial… Co-PI: Tara Lin, MD KU Cancer Center #leusm #AMLsm

Honored to present the James D. Cook, M.D. Memorial Lecture on MDS at the KansasUniversity #ASH24 Review. Grateful for the invitation and Dr. Abdulraheem Yacoub's inspiring opening remarks. Let the learning begin! 🎊🎊 UT Southwestern Medical Center UTSW Simmons Cancer Center

🔥 Excited for our Phase 1 study Ven + 7+3 for Newly Diagnosed AML demonstrating 85% CR (86% MRD-neg) Blood Journal @ MontefioreNYC Albert Einstein College of Medicine - Official Montefiore Health System Eric J. Feldman Mendel Goldfinger Marina Konopleva Amit Verma Aditi Shastri, MD Kira Gritsman #leusm doi.org/10.1182/blood.…

Beautiful day in #Rotterdam Visit Netherlands for the MDS Foundation Meeting #2025 — honored to be here in this stunning city. Great opening by G Garcia-Manero on #HR-MDS and an exciting agenda ahead. Looking forward to an inspiring few days! #MDS25 MDS Foundation UTSW Simmons Cancer Center

Several KU Cancer Center experts contributed to the recently published ASCO Educational Book article "Moving Away From Standard Induction in Newly Diagnosed Acute Myeloid Leukemia" ➔ ascopubs.org/doi/10.1200/ED… #CancerResearch #ClinicalTrials #ASCO25 #AML #KUBloodCancer

Presentation European Hematology Association #EHA25 & publication of our Phase 1b Aza+Ven+Revumenib study led by Joshua Zeidner MD by the Beat AML Consortium by 伊藤佑愛 👇🏾